Published in final edited form as:

Nat Rev Cancer. ; 12(6): 401–410. doi:10.1038/nrc3262.

Deconvoluting the context-dependent role for autophagy in cancer

Eileen White^{1,2,3}

Eileen White: whiteei@umdnj.edu

¹The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey 08903, USA

²University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA

³Department of Molecular Biology and Biochemistry, Rutgers University, 604 Allison Road, Piscataway, New Jersey 08854, USA

Abstract

Autophagy (also known as macroautophagy) captures intracellular components in autophagosomes and delivers them to lysosomes, where they are degraded and recycled. Autophagy can have two functions in cancer. It can be tumour suppressive through the elimination of oncogenic protein substrates, toxic unfolded proteins and damaged organelles. Alternatively, it can be tumour promoting in established cancers through autophagy-mediated intracellular recycling that provides substrates for metabolism and that maintains the functional pool of mitochondria. Therefore, defining the context-specific role for autophagy in cancer and the mechanisms involved will be important to guide autophagy-based therapeutic intervention.

Autophagy is a process by which cells capture intracellular proteins, lipids and organelles, and deliver them to the lysosomal compartment where they are degraded^{1,2}. The products of autophagic degradation of intracellular material are exported from lysosomes into the cytoplasm where they are recycled³. The intracellular recycling function of autophagy has a varying impact on cellular and organismal physiology that depends on the circumstances. There is a long-term need for autophagy to prevent tissue damage and disease, and there is also an acute requirement for autophagy to sustain homeostasis in stressful environments.

Autophagy occurs at a low basal level, but it can be induced and can implement selective or non-selective bulk degradation. Thus, the regulation of autophagy is crucial in controlling the level, timing and specificity of cargo elimination. Under normal conditions, the low level of basal autophagy acts as needed to remove unfolded proteins and damaged or superfluous organelles. This prevents their gradual accumulation over time, and maintains protein and organelle 'quality control'. Autophagy is dramatically induced by starvation and stress. Bulk intracellular degradation by autophagy during starvation recycles cellular components to supply the building blocks for metabolic pathways and for specific biomass generation to synthesize stress-response proteins³. This allows synthetic pathways and energy homeostasis to be maintained. For example, the generation of amino acids from protein degradation can

support new protein synthesis and essential metabolic pathways, including tricarboxylic acid (TCA) cycle function, and so compensates for the absence of external nutrients^{3,4}.

Selective autophagy recognizes, captures and eliminates stress-induced unfolded proteins and damaged organelles to ensure the preservation of normal and essential cellular components. To ensure the identification and selective elimination of such proteins and organelles, they are tagged by ubiquitin modification and are recognized by autophagy receptors that link the cargo to the autophagosome machinery⁵. This process is essential in stressful conditions, as the accumulation of damaged proteins and organelles is toxic to the cell.

The ability of autophagy to capture, degrade, eliminate and recycle intracellular components affects metabolism, enables host defence, remodels the proteome, regulates trafficking, alters signalling and influences cellular interactions. We are only beginning to understand the role of autophagy in normal and disease states. In this Review, I focus on the context-specific role of autophagy in suppressing and promoting cancer.

Consequences of autophagy disruption

Autophagy-related *ATG* genes encode the intracellular machinery that controls the initiation of autophagosome formation, cargo collection and trafficking to the lysosomal compartment, and most of these genes are conserved between yeast and humans^{2,6}. Tissues from mutant mice with defects in autophagy accumulate ubiquitylated protein aggregates, abnormal organelles, particularly mitochondria, as well as excess peroxisomes, endoplasmic reticulum (ER), ribosomes and lipid droplets⁷. The functional consequences of this failure of protein and organelle quality control are not entirely clear, but they are associated with the production of reactive oxygen species (ROS), metabolic insufficiency and increased proteotoxicity. This can promote cellular damage, reduce stress tolerance and compromise survival. Indeed, mice with systemic mosaic whole-body and tissue-specific autophagy defects display neurodegeneration, chronic inflammation, steatohepatitis and muscle damage, and have an increased susceptibility to tumour development and infection by pathogens^{7,8}. These animals also show an accumulation of autophagy substrates, including polyubiquitylated proteins, autophagy receptors such as p62 and NBR1, chaperones and other stress-response regulators, as well as aggregation-prone proteins^{9,10}.

In stressful conditions or in situations in which the expression of mutant proteins with increased protein misfolding and aggregation, autophagy has an important role in eliminating protein aggregates. Failure to eliminate protein aggregates through autophagy causes their accumulation as Mallory–Denk bodies in the liver, ubiquitylated and mutant protein aggregates in the brain, and as α 1-antitrypsin aggregates in the lung, liver and other tissues^{10–13}. Although the proteasome pathway can degrade individual, soluble proteins, autophagy is required to degrade aggregated proteins, and may supplement proteasome-mediated degradation in times of stress. Autophagy is stimulated by proteasome pathway inhibition to which autophagy-defective cells are highly sensitized, providing evidence that there is a partial, complementary interaction and interdependence between the two main mechanisms of protein degradation^{10,14}.

Tumour suppression by autophagy

Suppression of liver tumour initiation by autophagy

The demonstration that autophagy could have a role in tumour suppression came from the examination of mice with allelic loss of the essential autophagy gene beclin 1 (*Becn1*; also known as *Atg6*). These mice are partially defective for autophagy and develop

hepatocellular carcinomas with advancing age^{15,16}. Liver tumours arising from allelic loss of *Becn1* do not undergo loss of heterozygosity, suggesting obligate haploinsufficiency, and that tumour cells cannot tolerate the complete loss of *Becn1* and autophagy. Cancers in other tissue types have been reported in these mice^{15,16}; however, mosaic deletion of the essential autophagy gene *Atg5* in mice produces hepatomas only, suggesting that tumour suppression by autophagy is liver-specific¹⁷.

Allelic loss of *BECN1* has been reported in some human cancers^{18,19}; however, a comprehensive analysis of copy number variation, mutation frequencies and expression levels of essential autophagy genes using cancer genome and gene expression data is necessary to validate these findings. This is important because *BECN1* has autophagy-independent functions²⁰.

Autophagy and antioxidant defence

An important subtype of autophagy is the specific autophagy of mitochondria that is known as mitophagy. Dysfunctional mitochondria lose membrane potential, triggering the activation of PTEN-induced putative kinase 1 (PINK1). PINK1 activates the E3 ligase parkin (PARK2) to ubiquitylate mitochondrial outer membrane proteins, providing an 'eat me' signal for recognition by the autophagy machinery²¹. This causes the selective elimination of damaged mitochondria, thereby maintaining mitochondrial quality control. A reduction in mitochondrial number through mitophagy, and particularly the selective elimination of damaged mitochondria, is a potential means to reduce ROS and oxidative stress. The physiological settings in which mitophagy is important are only now beginning to emerge, but inactivating mutations in *PINK1* and *PARK2* are found in Parkinson's disease²¹. *PARK2* is also a tumour-suppressor gene²², and *Park2* deletion in mice causes hepatocellular carcinoma that is similar to allelic loss of *Becn1* (REF. 23). It is likely that toxic consequences of failed mitophagy and mismanagement of oxidative stress contribute to neuro-degenerative diseases, such as Parkinson's disease, and also contribute to tumour promotion when autophagy is defective.

In cells with an intact autophagy pathway that are not subject to stress, levels of p62 (a protein targeted by autophagy (BOX 1)) are low. p62 is a crucial activator of nuclear factor erythroid 2-related factor 2 (NRF2)^{12,24}. Cells protect themselves from oxidative stress not only by eliminating the mitochondrial ROS source through mitophagy, but also by turning on the transcription of antioxidant-defence genes. NRF2 is a transcription factor that is responsible for activating this response.

Box 1

Regulation of signalling and autophagy by p62

p62 is an adaptor protein that possesses many binding motifs that allow it to bring together proteins and assemble them into protein complexes that regulate signal transduction⁹⁶. p62 binds both polyubiquitin on autophagy cargo via its ubiquitin-associated (UBA) domain and the autophagosome protein light chain 3 (LC3; also known as MAP1LC3A) via its LC3-interacting region (LIR) domain, which directs cargo to autophagosomes for degradation. The PB1 domain of p62 also interacts with itself, promoting self-aggregation, and with the autophagy receptor neighbour of BRCA1 (NBR1), to promote packaging of cargo and delivery to the autophagy pathway. As p62 is an autophagy substrate, autophagy defects cause accumulation of p62, which perturbs signal transduction in multiple pathways. Through its PB1 domain, p62 can bind ERK1, MAP2K5, MAP3K3 and atypical protein kinase C, and thereby may influence nuclear factor- κ B (NF- κ B) activation, cell growth and polarity. The ZZ domain of p62 interacts

with RIP1 and TRAF6, and complex formation can promote NF- κ B activation, leading to cell growth, survival, inflammation and promotion of antioxidant defence. p62 interacts with kelch-like ECH-associated protein 1 (KEAP1) through its KEAP1-interacting region (KIR domain), which releases NRF2 and enables it to induce genes involved in antioxidant defence. p62 also interacts with regulatory-associated protein of mTOR (RAPTOR), thereby promoting nutrient sensing and cell growth by mTOR complex 1. By virtue of these interactions, p62 has a role in cancer, differentiation, inflammation, metabolism and cell growth. Autophagy defects increase p62 levels and promote some of these pathways, however, accumulation of p62 to high levels causes p62 aggregation that sequesters and inactivates p62-interacting proteins to inhibit some of these pathways.

NRF2 transcriptional activity is suppressed under normal conditions by direct binding to its inhibitor, kelch-like ECH-associated protein 1 (KEAP1), a component of the cullin 3 (CUL3)–RBX1 E3-ligase complex (FIG. 1). In the absence of oxidative stress, NRF2 is bound to KEAP1–CUL3–RBX1 and is degraded, and antioxidant-defence genes are not activated. Oxidative stress causes the modification of KEAP1 that releases NRF2, or causes the upregulation of *SQSTM1* (the gene that encodes p62). The binding of p62 to KEAP1 competitively displaces NRF2, which is then free to translocate to the nucleus where it turns on the expression of numerous ROS-detoxification genes, promoting cell survival²⁵ (FIG. 1).

NRF2 is also regulated by autophagy because p62 is a prominent autophagy substrate^{12,24,26}. Although in normal cells the activation of the KEAP1–NRF2 pathway can be tumour suppressive through the induction of antioxidant-defence systems, in cells that have a disrupted autophagy pathway, NRF2 may be protumorigenic. In autophagy-defective cells and mice, p62 accumulates to high levels because it is not degraded, generating more p62 that is available to bind to and inhibit KEAP1 and sequester it in aggregates, which promotes the activation of NRF2 (FIG.1). Thus, autophagy defects can enable cell survival by preventing p62 degradation and by promoting NRF2 activation and the induction of antioxidant defence. Indeed, p62 deficiency impairs the tumorigenicity of genetically altered cell lines and the development of lung tumours in mice after RAS activation^{10,27,28}. Moreover, liver-specific deletion of the essential autophagy gene *Atg7* causes p62 accumulation, nuclear localization of NRF2, upregulation of NRF2-target genes and tumorigenesis, which is blocked by p62 deficiency^{12,13,17}.

Interestingly, deficiency in p62 or in NRF2 greatly suppresses the development of oncogenic RAS-driven non-small-cell lung cancer in mouse models^{27,29}. It will, therefore, be important to test whether NRF2 deficiency prevents tumorigenesis that is induced by autophagy deficiency and p62 accumulation.

There are activating mutations in *NRF2* and inactivating mutations in *KEAP1* in human cancers, indicating that *NRF2* can function as an oncogene and *KEAP1* as a tumour suppressor gene^{25,30}. One prediction is that p62 upregulation by autophagy deficiency, or perhaps by activating mutations or gene amplification, is a major mechanism of tumour promotion by the NRF2 pathway. Another prediction is that autophagy suppression leading to upregulation of p62 and activation of NRF2-mediated survival might provide an alternative interpretation for the phenomenon of autophagic cell death. Increased cell survival with knockdown of essential autophagy genes has been attributed to the loss of autophagic cell death³¹. For example, the killing of cancer cells by some agents, and of a normal cell line through excessive RAS activation, can be decreased by autophagy inhibition^{32,33}. It will be important to test whether this is instead due to the induction of p62 and the activation of NRF2 (or of nuclear factor- κ B (NF- κ B))-dependent survival when

autophagy is inhibited (discussed below). To rule out this possibility, p62 elimination will need to have no effect on survival. If the activation of survival pathways by autophagy inhibition is not a factor, it will be interesting to explore the potential mechanism of cell killing by autophagy activation.

Although it is clear that degrading p62 by autophagy and suppressing NRF2 activity is a crucial tumour suppressive mechanism, there may be additional consequences to deregulation of p62 through activation of additional oncogenic signalling pathways. p62 is an important signalling adaptor protein that interacts with tumour necrosis factor receptor-associated factor 6 (TRAF6) and promotes NF- κ B activation³⁴, and autophagy defects result in NF- κ B induction in the liver¹⁰. Recent evidence suggests that p62 interacts with mTOR, RAPTOR and RAG proteins to promote mTOR signalling³⁵. It will be important to identify the role and function of p62 in human cancers, and when and how p62 deregulation is related to autophagy suppression and tumour promotion.

The importance of tumour suppression by autophagy

The gradual picture that is emerging is that autophagy is required to suppress p62 accumulation and inappropriate activation of NRF2, and perhaps other oncogenic signalling pathways, which can promote survival and tumorigenesis. Autophagy defects cause the accumulation of abnormal mitochondria that are a potential source of ROS. NRF2 activation may not be sufficient for a complete and sustained suppression of ROS when autophagy is blocked, which might eventually overwhelm the NRF2 antioxidant-defence system (FIG. 2). Autophagy defects cause the activation of the DNA damage response, DNA copy number variations and genetic instability, which is consistent with the eventual failure of cellular protection by NRF2 and the acquisition of genome mutations that drive tumorigenesis^{17,36,37} (FIG. 2). This situation of chronic tissue damage also provokes an inflammatory response that can further promote tumour growth through cytokine and chemokine production (FIG. 2). Chronic inflammation is known to contribute to liver cancer^{38,39}, and activation of inflammation is also observed with allelic loss of *Becn1* in the liver¹⁰, in tumour allografts with autophagy defects⁴⁰ and following expression of a hypomorphic allele of *Atg16l1* in the gut in a model of Crohn's disease⁴¹. Thus, tumour promotion conferred by autophagy defects may result from both mutagenesis and the creation of an inflammatory environment (FIG. 2). Alternatively, autophagy may facilitate oncogene-induced senescence to limit tumorigenesis in some settings⁴². Going forwards, it will be interesting to examine these different roles for autophagy in cancer models and human tumours to determine their importance and contribution.

Autophagy stimulation for cancer prevention

Autophagy limits inflammation, tissue damage and genome instability that can promote cancer initiation, suggesting that stimulating autophagy may be beneficial for cancer prevention^{17,36,37,40,43,44}. The aberrant accumulation of the autophagy substrate p62 in autophagy-deficient liver promotes liver damage and tumorigenesis^{10,13,17}, and deficiency in p62 impairs tumorigenesis^{10,27}, suggesting that inhibiting p62 may be valuable for cancer prevention and treatment. The damaging consequence of aggregation-prone mutant protein expression (such as mutant α 1-antitrypsin Z), which predisposes to cancer, is also mitigated by autophagy stimulation¹¹. The added burden of mutant protein expression may also compromise the effectiveness of autophagy, and further increase cancer risk by a feedforward mechanism.

Increased inflammation is associated with cancer when autophagy is suppressed^{10,40,41,45,46}, suggesting that anti-inflammatory agents and autophagy promoters might be effective in cancer prevention. There is also evidence that the suppression of cancer owing to caloric

restriction⁴⁷ and the health benefits of exercise^{48,49} may be attributed to autophagy. Thus, by clearing away cellular waste, particularly mutated aggregation-prone proteins and damaged mitochondria, and p62, autophagy may contribute to tumour suppression in some settings. Thus, functional autophagy status may be a predictor of cancer predisposition and the cancer prevention effectiveness of calorie restriction and exercise.

Tumour promotion by autophagy

Autophagy enables survival during starvation

Autophagy was originally found to be induced in yeast in response to starvation; autophagy supports the survival of yeast under starvation conditions by preserving amino acid levels and by upregulating starvation-response genes and mitochondrial function^{50–52}. Similarly, deletion of *Atg5* in mice revealed that autophagy was required for mammalian survival during the interval between placental separation and suckling⁵³. *Atg5*-deficient mice die shortly after birth, which coincides with a period of physiological starvation during which autophagy is upregulated. Tissues from these mice have lower amino acid and ATP levels, which are suggestive of a metabolic crisis. Autophagy is also induced by the fertilization of mouse embryos and is required for proteome remodelling, as well as preimplantation development and survival⁵⁴. Thus, recycling to support metabolism, and protein and organelle quality control — the main functions for autophagy — are highly conserved.

Autophagy is a cancer cell survival pathway

Autophagy is robustly activated in tumour cells by a multitude of stressors, including starvation, growth factor deprivation, hypoxia, damaging stimuli and proteasome inhibition. In the vast majority of cases, autophagy induction promotes survival in response to stress. Survival by autophagy in response to growth factor withdrawal or metabolic stress is particularly dramatic when apoptosis is disabled, which results in dormancy or quiescence, survival for weeks and then the resumption of cell growth on return to normal conditions^{40,55}. Ischaemia (that is, glucose deprivation and hypoxia), a common physiological stress in the tumour microenvironment, upregulates autophagy in cancer cells and enables survival *in vitro*^{36,37,40}. Autophagosomes are most prominent in tumour cells that are located in hypoxic tumour regions, and deletion of essential autophagy genes results in tumour cell death specifically in these hypoxic regions^{36,37,40}. This was the first indication that tumours can commandeer the survival function of autophagy to promote tumorigenesis.

High basal autophagy and autophagy addiction in cancer

Normal cells and tissues have low levels of basal autophagy, but autophagy is dramatically induced by stress and starvation. This is most evident in autophagy-reporter transgenic mice in which starvation increases autophagosome numbers in many different tissues^{56,57}. Thus, in normal cells and tissues, minimal autophagy is required in the absence of stress, but upregulation of autophagy in response to stress is crucial for survival. By contrast, many cancer cell lines have high basal levels of autophagy even under fed conditions that do not increase much further under stress. Moreover, activation of oncogenic RAS, which can induce tumour growth, is sufficient to upregulate basal autophagy^{28,58,59}, and these cells have a limited ability to further increase autophagy levels, which diminishes their adaptation to stress. This suggests that oncogene activation may be a stress that requires autophagy induction to maintain homeostasis, and, therefore, that RAS activation restricts stress adaptation. Indeed, many cancer cell lines with activated RAS are highly dependent on autophagy for survival under basal, but especially stress, conditions.

Autophagy deficiency almost abrogates the tumorigenicity of oncogenic RAS-expressing human and mouse cancer cell line models, suggesting that RAS activation and autophagy deficiency are synthetically lethal^{28,59} (FIG. 3). These observations may not be limited to RAS, as inactivation of *Fip200*, the mouse homologue of yeast *Atg17* (also known as *Rb1cc1*) in the polyoma middle T (PyMT) mouse mammary cancer model impairs tumour growth⁴⁶, and deletion of *Atg5* or *Atg7* in the liver causes hepatoma formation without progression to hepatocellular carcinoma¹⁷. These findings suggest that autophagy could be required to support the growth of aggressive cancers (FIG. 3). However, the mechanism by which autophagy supports tumorigenesis is not yet clear.

Autophagy is required to maintain mitochondrial function

Inactivation of autophagy in tumours results in the accumulation of morphologically abnormal mitochondria^{17,28,46,59}. A comparison of autophagy wild-type and deficient cancer cell lines that were used to generate these tumours revealed defective mitochondrial respiration^{28,59}, which is also observed in autophagy-deficient mouse muscle and yeast^{50,60}. Thus, maintaining the pool of respiring mitochondria is a function of autophagy that is conserved from yeast to mammals.

The root cause of mitochondrial defects needs to be addressed. Failure to remove damaged mitochondria can explain their accumulation in autophagy-defective cells; however, autophagy might have a direct role in regulating mitochondrial function by supplying substrates in the form of amino acids and fatty acids. The absence of these autophagy-supplied substrates might cause mitochondrial dysfunction, leading to toxic ROS production and mitochondrial damage, with the accumulation of damaged mitochondria amplified by the failure to purge them from the population³. As mitochondrial respiration is required for tumorigenesis that is induced by oncogenic RAS⁶¹, the deterioration of mitochondrial function in autophagy-defective tumours could explain their impaired tumorigenicity^{17,28,46,59,62}. However, the precise mechanisms by which autophagy supports mitochondrial function are currently unknown.

Autophagy-supplied substrates support mitochondrial metabolism

The collection, degradation and recycling of intracellular material in starvation is a main function of autophagy. Mitochondria are important for ATP production, energy homeostasis, the generation of building blocks from cataplerosis (such as the use of citrate for fatty acid synthesis and membrane biogenesis) and the production of ROS to activate signal transduction pathways. All of these functions are likely to be contributors to tumour-promoting functions of autophagy. Autophagy defects in tumour cells cause a deficit in ATP levels and energy charge, depletion of key TCA cycle intermediates such as citrate and aberrant ROS production (either high toxic or deficient ROS levels, depending on acute versus chronic autophagy inhibition)^{10,28,36,37,59}.

Autophagy can supply substrates to replenish TCA cycle intermediates through anaplerotic reactions to sustain mitochondrial function in stress and starvation. Degradation of proteins by autophagy generates amino acids that can feed into the TCA cycle at multiple points to sustain mitochondrial metabolism (FIG. 4). Lipids harvested from lipid droplets by lipophagy⁶³, or from organelle membrane degradation by autophagy, can be used to produce acetyl-CoA to maintain TCA cycle function (FIG. 4). It is also possible that autophagy-recycled sugars can generate pyruvate and acetyl-CoA from glycolysis to feed the TCA cycle. The challenge is to determine which of these mechanisms are crucial for autophagy-mediated tumour survival.

Why RAS-driven cancers are autophagy-dependent

RAS impairs acetyl-CoA production through several mechanisms: by stimulating lactate dehydrogenase (LDH), which depletes pyruvate; by activating hypoxia-inducible factors (HIFs) and pyruvate dehydrogenase kinase 1 (PDK1), which inhibits pyruvate dehydrogenase (PDH)^{64,65}; and by inhibiting liver kinase B1 (LKB1) and blocking AMP-activated protein kinase (AMPK) activation, preventing the mobilization of lipid stores and β -oxidation^{66,67}. Thus, RAS potentially leaves cells dependent on autophagy to provide substrates, such as amino acids and fatty acids, for acetyl-CoA biosynthesis (FIG. 4). Experiments to verify this are ongoing. RAS signalling may amplify this problem by rendering cancer cells dependent on autophagy to maintain functional mitochondria. One prediction is that RAS-driven cancers would be addicted not only to autophagy but also to glutamine for glutaminolysis to compensate for curtailed acetyl-CoA production. Thus, glutamine-derived α -ketoglutarate can promote the TCA cycle when there are reduced levels of acetyl-CoA that are normally supplied by pyruvate and β -oxidation (FIG. 4).

RAS may also starve mitochondria of TCA cycle substrates and shorten their lifespan, which is exacerbated by RAS-dependent HIF activation, as HIF1 activation impairs mitochondrial biogenesis⁶⁸. Thus, autophagy addiction of RAS-driven cancers may arise as a specific adaptation to, and compensation for, the metabolic reprogramming by RAS. If this is the case, the specific oncogenic events that are inherent to cancers may dictate whether autophagy is required, and the particular aspect of autophagy that is important.

Adaptation strategies of cancer cells to autophagy inhibition

As autophagy defects compromise mitochondrial function, an intriguing issue is whether cancer cells can adapt and circumvent this problem by altering their metabolism. Autophagy deficiency in both normal and cancer cells can upregulate glycolysis as a potential compensatory mechanism to cope with defective mitochondria^{58,60} (FIG. 4). Cancer cells may get by with a partially defective TCA cycle by relying on glutaminolysis to bypass citrate depletion and flux through that part of the TCA cycle (FIG. 4). One prediction from this is the glutamine dependence of autophagy-deficient cells. Glutamine-derived α -ketoglutarate can be converted to citrate for cataplerotic reactions by reductive carboxylation (FIG. 4). Indeed, cancer cells with defective mitochondria owing to mutational defects in electron transport chain complex III do exactly that⁶⁹. Another way to at least partially compensate for autophagy deficiency is to upregulate proteasome-mediated protein degradation or chaperone-mediated autophagy. Both pathways provide ways to derive amino acid substrates for anaplerosis from soluble proteins, use the same targeting mechanism of ubiquitin substrate modification, and their inhibition potentiates cell death with autophagy inhibition and can compromise cancer cell growth^{5,10,14,28,70}. It will be interesting to determine the extent and mechanisms by which cancer cells adapt to autophagy inhibition.

Autophagy in cancer therapy

Since the realization that autophagy is a survival pathway for tumour cells, there has been great interest in inhibiting autophagy for cancer therapy^{44,71–73}. Although small-molecule autophagy inhibitors are in development, the lysosomotropic and anti-malarial agent hydroxychloroquine (HCQ), which blocks the degradation of the products of autophagy by inhibiting lysosome function, is being actively assessed in the clinic^{71,73}. Whether HCQ will be an effective autophagy inhibitor in human tumours, how patients who would benefit will be identified and their tumours assessed, and how to determine the best drugs to combine with HCQ, have yet to be resolved. It will also be important to establish whether any anticancer activity of HCQ is due to autophagy impairment, as it may act by other

mechanisms⁷⁴. Our current understanding of the role of autophagy in cancer has provided a number of insights.

Stress augmentation

Autophagy inhibition may augment ambient or therapy-induced stress to promote cancer cell death. As autophagy promotes the survival of tumour cells that reside in hypoxic tumour regions, and because this subpopulation is commonly more refractory to cell death, combining autophagy inhibitors with radiation or chemotherapy would be expected to increase death among this resistant subpopulation. Increasing tumour metabolic stress by interfering with the tumour blood supply following surgery or with the use of angiogenesis inhibitors may increase the tumour cell subpopulation that is susceptible to autophagy inhibition. Dietary manipulation may also improve therapy in conjunction with autophagy inhibition. Starvation for leucine fails to activate autophagy in a mouse melanoma model, thereby creating sensitivity to autophagy inhibition that impairs tumorigenesis⁷⁵. This suggests that disengaging nutrient sensing from catabolism creates metabolic vulnerability. Compounding ER stress and proteotoxicity with autophagy inhibition is another option. Concurrent autophagy and proteasome inhibition, especially in diseases such as multiple myeloma, where there is an inherent burden of unfolded protein owing to immunoglobulin secretion, is also being explored¹⁴. Alternatively, blocking the ER stress response while inhibiting autophagy might promote tumour cell killing.

Potential of DNA damage

Autophagy defects can activate the DNA damage response and promote genome damage, potentially taxing DNA repair mechanisms^{36,37}. Many agents that either damage DNA or that inhibit DNA repair are successfully used in the clinic, and their activity may be augmented by autophagy inhibition. It will be interesting to determine whether autophagy inhibition induces genome damage by promoting toxic ROS production or whether there is direct regulation of the DNA repair machinery by autophagy that might dictate the optimal approach.

Blocking autophagy-mediated survival by targeted therapies

Activation of the PI3K pathway is a ubiquitous feature of human cancers, and many pathway component-specific inhibitors are currently in development or in the clinic⁷⁶. These include mTOR, PI3K and AKT inhibitors, all of which potently activate autophagy. As these agents often do not produce a durable response in patients, there is interest in increasing their efficacy. Autophagy activation by these agents is potentially counterproductive. In preclinical models, combining PI3K pathway inhibitors with HCQ or genetic ablation of autophagy has demonstrated increased tumour regression^{59,75,77–90}. Clinical trials to test this concept in patients are ongoing^{71,73}. The identification of susceptible patients and the mechanisms behind any antitumour activity needs to be determined to guide clinical application.

Susceptible cancer subtypes

A major limitation of our current knowledge is the ability to identify patients who would most benefit from autophagy inhibition. Good candidates are RAS-driven cancers, particularly pancreatic cancer in which the majority of patients have activating mutations in *KRAS*, and for which there is evidence for autophagy addiction from preclinical models⁵⁹. The ability to assess human tumour tissue for high autophagic flux rather than only static levels of autophagosomes would be a potential means to direct therapy. Determining the effectiveness of autophagy inhibitors in clinical samples is also necessary. The accumulation of autophagy substrates such as p62 can help to assess autophagy inhibition, although a

reliable panel of markers requires development. Autophagy is induced during cancer cell detachment (anoikis) and promotes survival, suggesting a possible role in facilitating metastasis⁹¹. As most cancer patients die from disseminated disease, this may be another important application of autophagy inhibitors.

Collateral damage

Autophagy inhibition, especially in combination therapy, may pose cytotoxicity issues, such as to the liver and brain. Stem cells may also be more sensitive to autophagy inhibition than differentiated tissue⁹². It is hoped that the metabolic and growth alterations inherent to most cancers will provide a sufficient therapeutic window. The role of autophagy in regulating the immune response to tumours is still an open question. Indeed, autophagy in tumour cells may be required to supply extracellular ATP to increase the antitumour immune response, as has been implied by the study of tumour xenografts treated with cytotoxic chemotherapy⁹³.

In summary

Autophagy can both suppress cancer initiation and promote the growth of established cancers, and we are at the early stages of using this information to benefit patients. These findings have raised new issues. For example, are autophagy genes cancer susceptibility loci and are they commonly altered in human cancer? Which autophagy-supplied substrates are important for sustaining metabolism? This is important to determine because blocking this process would be expected to kill autophagy-addicted cancer cells. Will metabolic flux analysis identify oncogenic anabolic and catabolic pathways and exploitable vulnerabilities? Is autophagy an escape mechanism for therapies that target metabolic pathways? Will autophagy modulation be valuable in cancer prevention or therapy? Can autophagy addiction be exploited as a liability in cancer? Does autophagy diminish the efficacy of targeted therapies, and, if so, how? This may be most relevant to mTOR inhibitors for which the activation of autophagy is direct, and improving efficacy is desirable⁷⁶. What is the mechanism by which high basal autophagy in cancers overrides autophagy inhibition by active mTOR? Is ammonia derived from glutaminolysis, which has been shown to potentially activate autophagy, one possible mechanism^{94,95}? How do autophagy defects promote inflammation? Is there a role of autophagy in tumour–stroma interactions? How does autophagy affect the immune response to cancer? What can we learn about the role of autophagy from genetically engineered mouse models for cancer? The answers to these and many other interesting questions seem set to maintain the current interest in autophagy and its links to tumour development and metabolism, with the promise of using this information to improve cancer treatment.

Acknowledgments

I thank members of the White laboratory for helpful discussions and advice. This work was supported by grants from the US National Institutes of Health (R37 CA53370, RO1 CA130893 and RC1 147961), DOD (W81XWH06-1-0514 and W81XWH05) and the V Foundation.

Glossary

Tricarboxylic acid (TCA) cycle

Also known as the citric acid cycle or the Krebs cycle, the TCA cycle is a series of chemical reactions that generate energy and building blocks through the oxidation of acetate derived from carbohydrates, fats and proteins into carbon dioxide and water

Reactive oxygen species (ROS)	Chemically reactive molecules containing oxygen that cause cellular damage or that activate signalling
Steatohepatitis	A pathological condition, also known as fatty liver disease, characterized by inflammation and fat accumulation in the liver
Proteasome	A large protein complex responsible for the degradation of soluble proteins
NF-κB	A transcription factor that controls the immune response to damage and infection
mTOR	A serine/threonine protein kinase that regulates cell growth, cell proliferation, cell survival, protein synthesis and transcription in response to nutrient and growth factor availability
Hypoxia	A pathological condition in which the body as a whole or a region of the body, such as a tumour, is deprived of an adequate oxygen supply
Cataplerosis	The process by which metabolic intermediates are removed from metabolic pathways
Glycolysis	The metabolic pathway that converts glucose into pyruvate and in the process produces ATP and reduced NADH
Glutaminolysis	A series of biochemical reactions in which the amino acid glutamine is degraded to glutamate then to α -ketoglutarate for further metabolism in the tricarboxylic acid cycle
Anaplerosis	The process of replenishment of depleted metabolic cycle or pathway intermediates
ER stress	A stress adaptation pathway activated by the accumulation of unfolded proteins in the endoplasmic reticulum (ER)

References

1. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. *Cell*. 2008; 132:27–42. [PubMed: 18191218]
2. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. *Curr Opin Cell Biol*. 2010; 22:132–139. [PubMed: 20056399]
3. Rabinowitz JD, White E. Autophagy and metabolism. *Science*. 2010; 330:1344–1348. [PubMed: 21127245]
4. Mathew R, White E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. *Curr Opin Genet Dev*. 2011; 21:113–119. [PubMed: 21255998]
5. Clague MJ, Urbe S. Ubiquitin: same molecule, different degradation pathways. *Cell*. 2010; 143:682–685. [PubMed: 21111229]
6. Mizushima N. Autophagy: process and function. *Genes Dev*. 2007; 21:2861–2873. [PubMed: 18006683]
7. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. *Cell*. 2011; 147:728–741. [PubMed: 22078875]
8. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. *Nature*. 2011; 469:323–335. [PubMed: 21248839]
9. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. *Mol Cell*. 2009; 34:259–269. [PubMed: 19450525]

10. Mathew R, et al. Autophagy suppresses tumorigenesis through elimination of p62. *Cell*. 2009; 137:1062–1075. Proteomics were used to identify proteins that accumulate in autophagy-defective tumour cells, one of which is p62 that is required for tumorigenesis. [PubMed: 19524509]
11. Hidvegi T, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z. and reduces hepatic fibrosis. *Science*. 2010; 329:229–232. [PubMed: 20522742]
12. Komatsu M, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nature Cell Biol*. 2010; 12:213–223. This paper identifies p62 accumulation in autophagy-defective cells and KEAP1 interaction that activates NRF2. [PubMed: 20173742]
13. Komatsu M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell*. 2007; 131:1149–1163. This paper identifies that p62 accumulation in autophagy-defective mouse liver is required for inclusion body formation and hepatic toxicity. [PubMed: 18083104]
14. Ding WX, et al. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. *Mol Cancer Ther*. 2009; 8:2036–2045. [PubMed: 19584239]
15. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. *Proc Natl Acad Sci USA*. 2003; 100:15077–15082. This paper describes the requirement for *Becn1* in mouse development and that allelic loss renders mice tumour prone. [PubMed: 14657337]
16. Qu X, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *J Clin Invest*. 2003; 112:1809–1820. This paper describes the requirement for *Becn1* in mouse development and that allelic loss renders mice tumour prone. [PubMed: 14638851]
17. Takamura A, et al. Autophagy-deficient mice develop multiple liver tumors. *Genes Dev*. 2011; 25:795–800. This paper demonstrates that *Atg5* or *Atg7* deficiency in mice causes hepatoma development that requires p62. [PubMed: 21498569]
18. Aita VM, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. *Genomics*. 1999; 59:59–65. [PubMed: 10395800]
19. Liang XH, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature*. 1999; 402:672–676. This paper reports a role for beclin 1 in autophagy and in inhibiting tumorigenesis when overexpressed. [PubMed: 10604474]
20. He C, Levine B. The Beclin 1 interactome. *Curr Opin Cell Biol*. 2010; 22:140–149. [PubMed: 20097051]
21. Youle RJ, Narendra DP. Mechanisms of mitophagy. *Nature Rev Mol Cell Biol*. 2010; 12:9–14. [PubMed: 21179058]
22. Cesari R, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27. *Proc Natl Acad Sci USA*. 2003; 100:5956–5961. [PubMed: 12719539]
23. Fujiwara M, et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. *Oncogene*. 2008; 27:6002–6011. [PubMed: 18574468]
24. Lau A, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. *Mol Cell Biol*. 2010; 30:3275–3285. This paper demonstrates that p62 binds and inhibits KEAP1 thereby promoting NRF2 activation in autophagy-defective cells. [PubMed: 20421418]
25. Villeneuve NF, Lau A, Zhang DD. Regulation of the Nrf2–Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. *Antioxid Redox Signal*. 2010; 13:1699–1712. [PubMed: 20486766]
26. Pankiv S, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J Biol Chem*. 2007; 282:24131–24145. [PubMed: 17580304]
27. Duran A, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. *Cancer Cell*. 2008; 13:343–354. This paper demonstrates that p62 deficiency prevents KRAS lung tumorigenesis. [PubMed: 18394557]
28. Guo JY, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. *Genes Dev*. 2011; 25:460–470. This paper reports autophagy addiction of RAS-

- driven cancers, specifically that RAS activation upregulates basal autophagy that is required for mitochondrial function and tumorigenesis. [PubMed: 21317241]
29. DeNicola GM, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature*. 2011; 475:106–109. This paper demonstrates that NRF2 is required for KRAS and BRAF lung tumorigenesis. [PubMed: 21734707]
 30. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. *Trends Biochem Sci*. 2009; 34:176–188. [PubMed: 19321346]
 31. Shen S, Kepp O, Kroemer G. The end of autophagic cell death? *Autophagy*. 2012; 8:1–3. [PubMed: 22082964]
 32. Turcotte S, et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. *Cancer Cell*. 2008; 14:90–102. [PubMed: 18598947]
 33. Elgendy M, Sheridan C, Brumatti G, Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. *Mol Cell*. 2011; 42:23–35. [PubMed: 21353614]
 34. Moscat J, Diaz-Meco M. T p62 at the crossroads of autophagy, apoptosis, and cancer. *Cell*. 2009; 137:1001–1004. [PubMed: 19524504]
 35. Duran A, et al. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. *Mol Cell*. 2011; 44:134–146. [PubMed: 21981924]
 36. Karantza-Wadsworth V, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. *Genes Dev*. 2007; 21:1621–1635. This paper describes that autophagy prevents genome damage and promotes tumour cell survival in a model of mammary cancer. [PubMed: 17606641]
 37. Mathew R, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. *Genes Dev*. 2007; 21:1367–1381. Autophagy defects cause activation of the DNA damage response, DNA copy number variations and an elevated mutation rate, suggesting that autophagy suppresses genome instability to limit tumorigenesis. [PubMed: 17510285]
 38. Sakurai T, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. *Cancer Cell*. 2008; 14:156–165. [PubMed: 18691550]
 39. Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. *Oncogene*. 2008; 27:6228–6244. [PubMed: 18931690]
 40. Degenhardt K, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell*. 2006; 10:51–64. Autophagy is induced in hypoxic tumour regions and is required for tumour cell survival and for limiting inflammation. [PubMed: 16843265]
 41. Cadwell K, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. *Nature*. 2008; 456:259–263. Atg16l1 is required in Paneth cells to prevent an injury response and may have a role in Crohn's disease. [PubMed: 18849966]
 42. Young AR, et al. Autophagy mediates the mitotic senescence transition. *Genes Dev*. 2009; 23:798–803. [PubMed: 19279323]
 43. Chen HY, White E. Role of autophagy in cancer prevention. *Cancer Prev Res (Phila)*. 2011; 4:973–983. [PubMed: 21733821]
 44. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. *Nature Rev Cancer*. 2007; 7:961–967. [PubMed: 17972889]
 45. Wei H, Gan B, Wu X, Guan JL. Inactivation of FIP200 leads to inflammatory skin disorder, but not tumorigenesis, in conditional knock-out mouse models. *J Biol Chem*. 2009; 284:6004–6013. [PubMed: 19106106]
 46. Wei H, et al. Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. *Genes Dev*. 2011; 25:1510–1527. [PubMed: 21764854]
 47. Blagosklonny MV. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR. *Cell Death Dis*. 2010; 1:e12. [PubMed: 21364614]
 48. He C, et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. *Nature*. 2012; 481:511–515. [PubMed: 22258505]
 49. Masiero E, et al. Autophagy is required to maintain muscle mass. *Cell Metab*. 2009; 10:507–515. [PubMed: 19945408]

50. Suzuki SW, Onodera J, Ohsumi Y. Starvation induced cell death in autophagy-defective yeast mutants is caused by mitochondria dysfunction. *PLoS ONE*. 2011; 6:e17412. Autophagy is required in yeast to prevent mitochondrial impairment and cell death. [PubMed: 21364763]
51. Onodera J, Ohsumi Y. Autophagy is required for maintenance of amino acid levels and protein synthesis under nitrogen starvation. *J Biol Chem*. 2005; 280:31582–31586. [PubMed: 16027116]
52. Kamada Y, Sekito T, Ohsumi Y. Autophagy in yeast: a TOR-mediated response to nutrient starvation. *Curr Top Microbiol Immunol*. 2004; 279:73–84. [PubMed: 14560952]
53. Kuma A, et al. The role of autophagy during the early neonatal starvation period. *Nature*. 2004; 432:1032–1036. Autophagy promotes survival of mice during neonatal starvation. [PubMed: 15525940]
54. Tsukamoto S, et al. Autophagy is essential for preimplantation development of mouse embryos. *Science*. 2008; 321:117–120. [PubMed: 18599786]
55. Lum JJ, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. *Cell*. 2005; 120:237–248. Autophagy enables long-term survival of lymphoid cells to growth factor deprivation. [PubMed: 15680329]
56. Mizushima N. Methods for monitoring autophagy using GFP-LC3 transgenic mice. *Methods Enzymol*. 2009; 452:13–23. [PubMed: 19200873]
57. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. *In vivo* analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. *Mol Biol Cell*. 2004; 15:1101–1111. [PubMed: 14699058]
58. Lock R, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. *Mol Biol Cell*. 2010; 22:165–178. RAS upregulates autophagy that promotes transformation. [PubMed: 21119005]
59. Yang S, et al. Pancreatic cancers require autophagy for tumor growth. *Genes Dev*. 2011; 25:717–729. This paper reports that pancreatic cancers display autophagy addiction with high basal autophagy that is required for growth, survival and tumorigenesis. [PubMed: 21406549]
60. Wu JJ, et al. Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. *Aging (Albany NY)*. 2009; 1:425–437. [PubMed: 20157526]
61. Weinberg F, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *Proc Natl Acad Sci USA*. 2010; 107:8788–8793. [PubMed: 20421486]
62. Valentin-Vega YA, et al. Mitochondrial dysfunction in ataxia telangiectasia. *Blood*. 2011; 119:1490–1500. [PubMed: 22144182]
63. Singh R, et al. Autophagy regulates lipid metabolism. *Nature*. 2009; 458:1131–1135. [PubMed: 19339967]
64. Chun SY, et al. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1 α and HIF-2 α target genes. *Mol Cancer*. 2010; 9:293. [PubMed: 21073737]
65. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. *Curr Opin Genet Dev*. 2010; 20:51–56. [PubMed: 19942427]
66. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. *J Biol Chem*. 2001; 276:9519–9525. [PubMed: 11120745]
67. Zheng B, et al. Oncogenic B-Raf negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. *Mol Cell*. 2009; 33:237–247. [PubMed: 19187764]
68. Zhang H, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. *Cancer Cell*. 2007; 11:407–420. [PubMed: 17482131]
69. Mullen AR, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature*. 2011; 481:385–388. [PubMed: 22101431]
70. Kon M, et al. Chaperone-mediated autophagy is required for tumor growth. *Sci Transl Med*. 2011; 3:109ra117.
71. Amaravadi RK, et al. Principles and current strategies for targeting autophagy for cancer treatment. *Clin Cancer Res*. 2011; 17:654–666. [PubMed: 21325294]

72. Garber K. Inducing indigestion: companies embrace autophagy inhibitors. *J Natl Cancer Inst.* 2011; 103:708–710. [PubMed: 21515831]
73. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. *Clin Cancer Res.* 2009; 15:5308–5316. [PubMed: 19706824]
74. Maycotte P, et al. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. *Autophagy.* 2012; 8:200–212. [PubMed: 22252008]
75. Sheen JH, Zoncu R, Kim D, Sabatini DM. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. *Cancer Cell.* 2011; 19:613–628. Autophagy induction by leucine starvation is required for the survival of melanomas. [PubMed: 21575862]
76. Feldman ME, Shokat KM. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). *Curr Top Microbiol Immunol.* 2010; 347:241–262. [PubMed: 20549474]
77. Altman BJ, et al. Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. *Oncogene.* 2011; 30:1855–1867. [PubMed: 21151168]
78. Amaravadi RK, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *J Clin Invest.* 2007; 117:326–336. [PubMed: 17235397]
79. Bellodi C, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. *J Clin Invest.* 2009; 119:1109–1123. [PubMed: 19363292]
80. Carew JS, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. *Blood.* 2007; 110:313–322. [PubMed: 17363733]
81. Degtyarev M, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. *J Cell Biol.* 2008; 183:101–116. [PubMed: 18838554]
82. Fan QW, et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. *Sci Signal.* 2010; 3:ra81. [PubMed: 21062993]
83. Han W, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. *PLoS ONE.* 2011; 6:e18691. [PubMed: 21655094]
84. Ma XH, et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. *Clin Cancer Res.* 2011; 17:3478–3489. [PubMed: 21325076]
85. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. *J Clin Invest.* 2008; 118:79–88. [PubMed: 18097482]
86. Pan Y, et al. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. *Clin Cancer Res.* 2011; 17:3248–3258. [PubMed: 21288924]
87. Parkhitko A, et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. *Proc Natl Acad Sci USA.* 2011; 108:12455–12460. [PubMed: 21746920]
88. Saleem A, et al. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. *Prostate.* Jan 12.2012 10.1002/pros.22487
89. Shi YH, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. *Autophagy.* 2011; 7:1159–1172. [PubMed: 21691147]
90. Wu Z, et al. Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. *Genes Cancer.* 2010; 1:40–49. [PubMed: 20811583]
91. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. *Mol Biol Cell.* 2008; 19:797–806. [PubMed: 18094039]
92. Mortensen M, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. *J Exp Med.* 2011; 208:455–467. [PubMed: 21339326]
93. Michaud M, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. *Science.* 2011; 334:1573–1577. Autophagy is required to promote antitumour immunity in response to cytotoxic chemotherapy. [PubMed: 22174255]

94. Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. *Sci Signal*. 2010; 3:ra31. Ammonia produced from glutaminolysis induces autophagy. [PubMed: 20424262]
95. Cheong H, Lindsten T, Wu J, Lu C, Thompson CB. Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. *Proc Natl Acad Sci USA*. 2011; 108:11121–11126. [PubMed: 21690395]
96. Moscat J, Diaz-Meco MT. p62: a versatile multitasker takes on cancer. *Trends Biochem Sci*. Mar 14.2012 10.1016/j.tibs.2012.02.008

At a glance

- Autophagy is a cellular self-cannibalization process that captures and digests cellular proteins and organelles in lysosomes.
- Autophagy levels are normally low but are dramatically induced by starvation and stress.
- Recycling of cellular material by autophagy sustains cellular and mammalian metabolism necessary for survival in starvation.
- The elimination of damaged proteins and organelles by autophagy is required for cellular homeostasis.
- Autophagy can be tumour suppressive by preventing chronic tissue damage and cancer initiation.
- Autophagy is induced in and required for the survival of tumour cells in hypoxic tumour regions.
- Many cancer cells upregulate autophagy that is required to support metabolism, tumorigenesis and survival to therapy.
- In aggressive cancers, autophagy inhibition may be therapeutically advantageous.

Figure 1. Regulation of NRF2 by autophagy, KEAP1 and p62

Under normal conditions, nuclear factor erythroid 2-related factor 2 (NRF2) is bound to kelch-like ECH-associated protein 1 (KEAP1) and is inactivated as a transcription factor for antioxidant-defence genes by proteasome-mediated degradation. p62 is degraded through autophagy under normal conditions. In the presence of oxidative stress, KEAP1 is either modified so that it can no longer bind NRF2 or it is sequestered by p62, the expression of which is increased in response to oxidative stress. This displaces KEAP1 from NRF2 so that NRF2 can activate antioxidant-defence genes and promote survival. Oxidative stress also activates nuclear factor- κ B (NF- κ B) as a result of p62 upregulation and tumour necrosis factor receptor-associated factor 6 (TRAF6) complex formation, or by other mechanisms, to turn on antioxidant-defence gene expression. p62 is still subject to autophagy in cells experiencing cellular stress (dashed arrow). In autophagy-defective cells and tissues, the autophagy substrate p62 is not degraded, and so accumulates to high levels. p62 binds and sequesters KEAP1 in aggregates, resulting in the constitutive activation of NRF2 and antioxidant defence. This p62 induction can also activate NF- κ B, antioxidant defence and survival.

Figure 2. Mechanism of autophagy-mediated tumour suppression

a Autophagy, either basal or stress-induced, prevents the accumulation of oncogenic proteins such as p62, as well as damaged proteins and organelles. **b** In autophagydefective tissues, p62 and damaged proteins and organelles accumulate. This is associated with the activation of oncogenic signalling pathways (nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor- κ B (NF- κ B)) that promote survival but that are probably eventually overwhelmed by sustained oxidative stress. This leads to reactive oxygen species (ROS) production, chronic tissue damage, inflammation and genome instability, creating a tumour-initiating and tumour-promoting environment.

Figure 3. The role of autophagy in supporting the growth of aggressive cancers

a | Autophagy is upregulated in RAS-driven cancers and is also induced in hypoxic tumour regions where it supports tumour cell survival. **b** | Autophagydeficient tumour cells accumulate defective mitochondria and are prone to cell death in hypoxic regions. This can lead to impairment of the growth of RAS-driven cancers and perhaps other cancers.

Figure 4. Mechanism of autophagy addiction of RAS-driven cancers

The generation and use of acetyl CoA (depicted by red arrows and red boxes) is an essential component of the tricarboxylic acid (TCA) cycle. There are three known mechanisms by which RAS diminishes the pool of acetyl-CoA (shown in the green boxes). First, RAS can activate lactate dehydrogenase (LDH) that converts pyruvate to lactate, which is excreted. Second, RAS can activate hypoxia-inducible factor (HIF), inhibiting pyruvate dehydrogenase (PDH) and the conversion of pyruvate to acetyl-CoA. Third, RAS inhibits liver kinase B1 (LKB1), blocking AMP kinase (AMPK) and β -oxidation. Autophagy defects result in reduced citrate levels, impaired TCA cycle function and loss of mitochondrial respiration^{28,59}. Autophagy can potentially compensate for the metabolic reprogramming by RAS by degrading proteins and lipids that provide amino acid and fatty acid substrates, producing acetyl-CoA (purple boxes). Tumour cells might also compensate for autophagy impairment by upregulating glycolysis, glutaminolysis or reductive carboxylation of α -ketoglutarate (α -KG) from glutamine (blue boxes). LC, long chain; OAA, oxaloacetate; PDK1, pyruvate dehydrogenase kinase 1.